CD274 and neoplasm: Based on our results, we would predict that combining pGSN inhibitors with other immune checkpoint blockers, such as anti-PD-1 and anti-PDL1, will significantly inhibit tumor growth and unleash the anti-tumor properties of CD8+ T cells, NK cells and M1 macrophages.